JAYMAC PHARMA
Drug class
Betaine
Betaine is a specific active substance and metabolic agent rather than a broad therapeutic drug class. Read more about Betaine
5 drugs in this class 5 manufacturers
Drugs in Betaine
CYSTADANE (betaine)
BETAINE · HOMOCYSTINURIA
ORPHAN EUROPE/R
BETAINE ANHYDROUS (betaine)
BETAINE · HOMOCYSTINURIA
ETON PHARMACEUT
BETAINE ANHYDROUS (betaine)
BETAINE · HOMOCYSTINURIA
OAKRUM PHARMA,
BETAINE ANHYDROUS (betaine)
BETAINE · HOMOCYSTINURIA
Cosette Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Betaine preselected. Add indication or manufacturer filters there.
Betaine is a specific active substance and metabolic agent rather than a broad therapeutic drug class.
Pharmacologically, it functions as an organic methyl donor that remethylates homocysteine to methionine via the liver enzyme betaine-homocysteine methyltransferase.
Therapeutically, it is indicated to lower elevated blood and urine homocysteine concentrations in pediatric and adult patients with homocystinuria, including disorders arising from cystathionine beta-synthase deficiency, 5,10-methylenetetrahydrofolate reductase deficiency, or cobalamin cofactor metabolism defects.
By reducing toxic accumulations of homocysteine, it helps prevent serious complications such as thromboembolism, skeletal abnormalities, and neurological deterioration.
-
fda.gov
Betaine is a specific active substance and metabolic agent rather than a broad therapeutic drug class
-
fda.gov
Betaine is a specific active substance and metabolic agent rather than a broad therapeutic drug class
-
nih.gov
Pharmacologically, it functions as an organic methyl donor that remethylates homocysteine to methionine via the liver enzyme betaine-homocysteine methyltransferase
-
patsnap.com
Pharmacologically, it functions as an organic methyl donor that remethylates homocysteine to methionine via the liver enzyme betaine-homocysteine methyltransferase
-
fda.gov
Therapeutically, it is indicated to lower elevated blood and urine homocysteine concentrations in pediatric and adult patients with homocystinuria, including disorders arising from cystathionine beta-synthase deficiency, 5,10-methylenetetrahydrofolate reductase deficiency, or cobalamin cofactor metabolism defects
-
nih.gov
Therapeutically, it is indicated to lower elevated blood and urine homocysteine concentrations in pediatric and adult patients with homocystinuria, including disorders arising from cystathionine beta-synthase deficiency, 5,10-methylenetetrahydrofolate reductase deficiency, or cobalamin cofactor metabolism defects By reducing toxic accumulations of homocysteine, it helps prevent serious complications such as thromboembolism, skeletal abnormalities, and neurological deterioration
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.